4568.T Daiichi Sankyo Company, Limited
¥2,654 -1.81%
Asia · Pharmaceuticals
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Hover to inspect. EOD data.
1D
-1.81%
YTD
-36.40%
P/E
—
P/B
—
ROE
—
Div yield
—
Beta
0.09
Market cap
—
RSI (14)
39
Next earnings
—
Previous session
close of Oct 8, 2026 · EOD, no live order bookOpen
¥2,731
Close
¥2,654
VWAP (n/a)
—
Day high
¥2,731
Day low
¥2,623
Volume
7.8M
VWAP = daily turnover ÷ volume — the volume-weighted average, the closest EOD read on where trading actually clustered. A true order book is live-only and needs a broker feed. Turnover/VWAP available for MOEX listings.
Latest headlines
Will there be more to Daiichi’s story than DXd ADCs?
Yahoo Finance · Oct 5
Summit Therapeutics (SMMT) Is Up 7.3% After $2 Billion AstraZeneca Partnership and Trial Collaboration
Yahoo Finance · Oct 2
Summit Teams Up With Daiichi Sankyo, AstraZeneca For Cancer Therapy Trial – CEO Calls It An ‘Important Expansion’
Yahoo Finance · Oct 2
Daiichi Sankyo (TSE:4568) Faces Fresh Court Uncertainty After Appeal In Fortis Case
Yahoo Finance · Oct 2
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Yahoo Finance · Oct 2
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Yahoo Finance · Oct 2
Headlines via Yahoo Finance · links open the source · not an endorsement.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell 4568.T. Try it in the Lab to size a position and see the risk.